Hans F. Merk

TL;DR: This guideline covers the definition and classification of urticaria, taking into account the recent progress in identifying its causes, eliciting factors, and pathomechanisms, and outlines evidence‐based diagnostic approaches for different subtypes ofUrticaria.

TL;DR: In patients with hereditary angioedema having acute attacks, a significant benefit of icatibant as compared with tranexamic acid in one trial and a nonsignificantbenefit of ic atibant in the other trial are found with regard to the primary end point.

TL;DR: This guideline has a profound impact on the quality of life and effective treatment is, therefore, required and the recommended first line treatment is new generation, nonsedating H1‐antihistamines, and second‐line therapies should be added to the antihistamine treatment.

TL;DR: The recommended first line treatment are nonsedating H1 antihistamines, but dosages increased up to fourfold over the recommended doses may be necessary for different urticaria subtypes and in view of individual variation in the course of the disease and response to treatment.

TL;DR: Ten years after the publication of the ARIA World Health Organization workshop report, it is important to make a summary of its achievements and identify the still unmet clinical, research, and implementation needs to strengthen the 2011 European Union Priority on allergy and asthma in children.